These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8739277)
21. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726 [TBL] [Abstract][Full Text] [Related]
22. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263 [TBL] [Abstract][Full Text] [Related]
23. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
24. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417 [TBL] [Abstract][Full Text] [Related]
25. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146 [TBL] [Abstract][Full Text] [Related]
26. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy. Kao HH; Chen KS; Tsai CJ; Lee CC; Chang HY Chang Gung Med J; 2000 Oct; 23(10):608-13. PubMed ID: 11126152 [TBL] [Abstract][Full Text] [Related]
27. Functional iron deficiency in hemodialysis patients with high ferritin. Kopelman RC; Smith L; Peoples L; Biesecker R; Rizkala AR Hemodial Int; 2007 Apr; 11(2):238-46. PubMed ID: 17403177 [TBL] [Abstract][Full Text] [Related]
28. Vitamin B(6) therapy does not improve hematocrit in hemodialysis patients supplemented with iron and erythropoietin. Weissgarten J; Modai D; Oz D; Chen Levy Z; Cohn M; Marcus O; Dishi V; Galperin E; Averbukh Z Nephron; 2001 Apr; 87(4):328-32. PubMed ID: 11287776 [TBL] [Abstract][Full Text] [Related]
30. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Fishbane S; Lynn RI Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123 [TBL] [Abstract][Full Text] [Related]
31. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097 [TBL] [Abstract][Full Text] [Related]
32. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776 [TBL] [Abstract][Full Text] [Related]
33. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. Folkert VW; Michael B; Agarwal R; Coyne DW; Dahl N; Myirski P; Warnock DG; Am J Kidney Dis; 2003 Mar; 41(3):651-7. PubMed ID: 12612989 [TBL] [Abstract][Full Text] [Related]
34. Effects of erythropoietin therapy on iron absorption in chronic renal failure. Skikne BS; Ahluwalia N; Fergusson B; Chonko A; Cook JD J Lab Clin Med; 2000 Jun; 135(6):452-8. PubMed ID: 10850644 [TBL] [Abstract][Full Text] [Related]
35. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products. McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312 [TBL] [Abstract][Full Text] [Related]
36. Improved response to erythropoietin therapy with long-term continuous iron supplementation. Descombes E; Fellay G Nephron; 2000 Feb; 84(2):196-7. PubMed ID: 10657727 [No Abstract] [Full Text] [Related]
37. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity. Tarng DC; Huang TP Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432 [TBL] [Abstract][Full Text] [Related]
38. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients. Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471 [TBL] [Abstract][Full Text] [Related]
39. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Trivedi HS; Brooks BJ Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145 [TBL] [Abstract][Full Text] [Related]
40. Antiplatelet therapy alters iron requirements in hemodialysis patients. Goicoechea M; Caramelo C; Ochando A; Andrea C; Garvía R; Ortiz A Am J Kidney Dis; 2000 Jul; 36(1):80-7. PubMed ID: 10873876 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]